[Management of proteasome inhibitor-induced peripheral neuropathy].

Bortezomib is a proteasome inhibitor which is active in the treatment for multiple myeloma. Peripheral sensory neuropathy is the most common and significant toxicity of bortezomib. The once-weekly infusion of bortezomib significantly reduces the incidence of peripheral neuropathy compared with the twice-weekly infusion and is not associated with any reduction in the efficacy. Peripheral neuropathy is less common when bortezomib is given by subcutaneous injection instead of intravenous injection. No loss of efficacy is observed. There is no established treatment recommended for the prevention of bortezomib-induced peripheral neuropathy. Standard management is dose modification and treatment discontinuation with a careful monitoring.